|Bid||0.00 x 1400|
|Ask||0.00 x 1200|
|Day's Range||17.27 - 17.78|
|52 Week Range||11.03 - 32.95|
|Beta (3Y Monthly)||2.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.35|
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 8.20% and 44.39%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics, Inc. (NTLA), reported operational highlights and financial results for the second quarter ended June 30, 2019. “We continue to build our in vivo and engineered cell therapy pipeline in support of our mission to develop curative genome editing therapies for patients,” said Intellia President and Chief Executive Officer John Leonard, M.D. “With IND-enabling toxicology studies underway for NTLA-2001, we are well-positioned to submit an IND in mid-2020 for the first systemically delivered CRISPR/Cas9-based therapy for transthyretin amyloidosis.
The legal battle over a method of altering a person’s genes that’s worth billions of dollars escalated this week, with the University of California alleging that the Cambridge-based Broad Institute withheld information in an attempt to deceive U.S. patent officials.
The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.
CAMBRIDGE, Mass., July 30, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
CAMBRIDGE, Mass., July 25, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
Intellia Therapeutics Inc’s (NASDAQ: NTLA ) gene editing drug seems to have the potential to disrupt the treatment of hereditary transthyretin amyloidosis, according to Baird. The Analyst Madhu Kumar initiated ...
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
CAMBRIDGE, Mass., May 30, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc., (NTLA) has named Laura Sepp-Lorenzino, Ph.D., as its new executive vice president and chief scientific officer. Dr. Sepp-Lorenzino brings decades of leadership and research and development experience, and joins Intellia to head its drug research organization. Andrew Schiermeier, Ph.D., executive vice president of development and corporate strategy, will continue to lead the drug development organization.
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
While the rest of the markets retreated on a round of risk-off selling in response to President Donald Trump’s threats to raise Chinese tariffs, biotechnology stocks and sector-related exchange traded ...
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 7.55% and -14.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics, Inc. (NTLA), reported operational highlights and financial results for the first quarter ended March 31, 2019. “2019 is off to a productive start in support of our mission to advance genome editing to treat a range of severe and life-threatening diseases. In particular, we presented data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy showing unprecedented CRISPR-mediated, targeted gene insertion in the liver of non-human primates, achieving normal circulating human levels of protein production,” said Intellia President and Chief Executive Officer John Leonard, M.D. “These achievements highlight Intellia’s leadership in CRISPR/Cas9 genome editing as we advance our pipeline towards the clinic.
Intellia Therapeutics, Inc. (NTLA), will present today new data, including the first demonstration of targeted gene insertion with CRISPR/Cas9 in the liver of non-human primates (NHPs), at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place April 29-May 2, 2019, in Washington, D.C. Researchers also will present today new in vitro data from Intellia’s lead engineered cell therapy program in acute myeloid leukemia (AML). Later this week at the 2019 ASGCT meeting, Intellia will present new data from its primary hyperoxaluria (PH1) program.
CAMBRIDGE, Mass., April 25, 2019 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
The three pure-play CRISPR stocks have been on the decline since early 2018. Shares of Intellia Therapeutics (NTLA), Editas Medicine (EDIT) and leader CRISPR Therapeutics (CRSP) have magnified the declines of the broader stock indexes late last year. Warning! GuruFocus has detected 3 Warning Signs with NTLA.